"Memorial Sloan Kettering Commack provides the same outstanding cancer care as other Memorial Sloan Kettering facilities in an outpatient center that is convenient for residents of Long Island. For general information, call Memorial Sloan Kettering at 212-639-2000, 24 hours a day, seven days a week. To make an appointment, call us at 833-494-2758, Monday through Friday between 8:00 AM and 6:00 PM ET."

During the past decade, Memorial Sloan Kettering Commack conducted 452 clinical trials. In the 10-year time frame, 452 clinical trials started and 113 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 207 clinical trials started and 71 clinical trials were completed. i.e. 34.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Memorial Sloan Kettering Commack" #1 sponsor was "Memorial Sloan Kettering Cancer Center" with 456 trials, followed by "National Cancer Institute (NCI)" with 52 trials sponsored, "NRG Oncology" with 18 trials sponsored, "Alliance for Clinical Trials in Oncology" with 15 trials sponsored and "Hoffmann-La Roche" with 15 trials sponsored. Other sponsors include 58 different institutions and companies that sponsored additional 31 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Memorial Sloan Kettering Commack" #1 collaborator was "National Cancer Institute (NCI)" with 66 trials as a collaborator, "NRG Oncology" with 24 trials as a collaborator, "Genentech, Inc." with 21 trials as a collaborator, "Weill Medical College of Cornell University" with 18 trials as a collaborator and "Merck Sharp & Dohme LLC" with 16 trials as a collaborator. Other collaborators include 553 different institutions and companies that were collaborators in the rest 283 trials.

According to Clinical.Site data, the most researched conditions in "Memorial Sloan Kettering Commack" are "Breast Cancer" (62 trials), "Prostate Cancer" (27 trials), "Lung Cancer" (26 trials), "Multiple Myeloma" (21 trials) and "Head and Neck Cancer" (17 trials). Many other conditions were trialed in "Memorial Sloan Kettering Commack" in a lesser frequency.

Most popular intervention types in "Memorial Sloan Kettering Commack" are "Drug" (412 trials), "Other" (147 trials), "Radiation" (122 trials), "Procedure" (94 trials) and "Behavioral" (58 trials). Other intervention types were less common.

The name of intervention was led by "Quality-of-Life Assessment" (34 trials), "Nivolumab" (30 trials), "Pembrolizumab" (27 trials), "Cisplatin" (26 trials) and "Carboplatin" (25 trials). Other intervention names were less common.

The vast majority of trials in "Memorial Sloan Kettering Commack" are 479 trials for "All" genders, 105 trials for "Female" genders and 32 trials for "Male" genders.

Currently, there are NaN active trials in "Memorial Sloan Kettering Commack". undefined are not yet recruiting, 217 are recruiting, 225 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 147 completed trials in Memorial Sloan Kettering Commack, 2 suspended trials, and 17 terminated clinical trials to date.

Out of the total trials that were conducted in Memorial Sloan Kettering Commack, 115 "Phase 1" clinical trials were conducted, 306 "Phase 2" clinical trials and 100 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 58 trials that are defined as “Not Applicable".